1. Pink Sheet

English HTA Finally Greenlights Conditional Funding for MSD’s Welireg

 
• By Francesca Bruce

MSD welcomes the decision but says the drug should have gone through NICE’s Highly Specialized Technologies route that allows more flexibility regarding uncertainty around rare disease drugs.

POUND PILL
Despite positive recommendations, MSD maintains Welireg should have been subject to NICE's appraisal process for very rare disease treatments • Source: Shutterstock

NICE, the health technology assessment (HTA) body for England and Wales, has finally okayed provisional funding for MSD’s Welireg (belzutifan) through the Cancer Drugs Fund for treating tumors associated with von Hippel-Lindau disease. The decision reverses a negative decision by NICE in November 2023 and follows a positive recommendation by NICE’s Scottish counterpart, the SMC, in October 2023.

The move also comes more than three years after the rare disease treatment became the first drug to earn an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe

New EU Filings

 
• By Neena Brizmohun

Arimoclomol, Zevra Therapeutics's treatment for Niemann-Pick disease Type C, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Sanofi Secures EU Fast-Track Status For ‘Game-Changing’ Sleeping Sickness Drug

 
• By Neena Brizmohun

If approved, Sanofi’s acoziborole could become the first single-dose oral treatment for sleeping sickness.

UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach

 
• By Eliza Slawther

Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.